Full-Time

Senior Director Nonclinical Science

Posted on 2/3/2025

Alector

Alector

51-200 employees

Biopharmaceutical R&D for neurodegenerative therapies

Compensation Overview

$262.1k - $283.5k/yr

San Bruno, CA, USA

Hybrid

Hybrid work model; specific number of in-office days not mentioned.

Category
Biology & Biotech (4)
, , ,
Requirements
  • PhD in Toxicology or related scientific field
  • At least 15+ years of post-training experience in academia, biotech or pharma
  • Industry experience in drug discovery and development
  • Demonstrated leadership and expertise in non-clinical safety
  • Broad understanding of toxicology/pathology, bioanalytical, ADME, regulatory and clinical pharmacology
  • Proven ability to lead and collaborate on multi-function project teams
  • Exceptional critical thinking and decision making skills
  • Exceptional oral presentation and written communication skills
Responsibilities
  • Lead and supervise the Toxicology and BioAnalytical teams
  • Provide strategic guidance on Nonclinical evaluations of pipeline programs
  • Design, execute Nonclinical studies and interpret study results together with the Toxicology team
  • Oversee the preparation, review and approval of Nonclinical Regulatory documents
  • Collaborate with the Toxicology and Regulatory teams for interactions with Health Authorities
  • Supervise the BioAnalytical team for PK/PD/ADA assay development
  • Manage Nonclinical budget, FTE and other internal and external resources effectively
  • Establish and maintain close partnership with key collaborators across the organization
Desired Qualifications
  • Desire to work in a fast-paced environment with can-do attitude

Alector is a biopharmaceutical company that develops therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's. It uses insights from immunology, neurology, and human genetics to create medicines that help the body heal itself. The company focuses on researching and developing novel therapeutic candidates, mainly through early-stage clinical trials to quickly gather disease-specific data and improve the chances of success. Revenue and funding come from partnerships, grants, and eventual product commercialization. Alector aims to advance treatments for unmet medical needs in neurodegenerative diseases by pursuing a pipeline that combines scientific findings with strategic drug development.

Company Size

51-200

Company Stage

IPO

Headquarters

San Francisco, California

Founded

2013

Your Connections

People at Alector who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • AL037/AL137-ABC anti-amyloid antibody targets validated epitope with reduced ARIA risk versus competitors.
  • Cash position of $206.5 million funds operations through 2027 and preclinical pipeline advancement.
  • Analyst consensus price target 48% above current stock price signals potential undervaluation opportunity.

What critics are saying

  • AL002 Phase 2 failure and GSK latozinemab efficacy stumble eliminate two major clinical assets.
  • Hercules Capital debt covenants trigger default from Q1 2026 revenue miss, forcing $10M repayment.
  • 13% workforce layoff signals cash constraints and accelerates talent exodus to better-funded competitors.

What makes Alector unique

  • Proprietary Alector Brain Carrier technology enables blood-brain barrier penetration for siRNA and protein therapeutics.
  • Genetically-validated target selection from human genetics, neuroscience, and immunology insights reduces clinical failure risk.
  • AL050 GCase enzyme replacement therapy addresses GBA mutations in Parkinson's and Lewy body dementia.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

5%

2 year growth

7%
Yahoo Finance
Feb 25th, 2026
Alector beats Q4 expectations with $6.2M revenue, narrows loss to 34 cents per share

Alector, a South San Francisco-based biotechnology company, reported a fourth-quarter loss of $37.3 million, or 34 cents per share, beating analyst expectations of a 39-cent loss. The company posted revenue of $6.2 million, exceeding forecasts of $3.1 million from three analysts surveyed by Zacks Investment Research. For the full year, Alector's loss widened to $142.9 million, or $1.39 per share, with revenue of $21 million. The company's shares closed at $2.39 on Wednesday, up from $1.77 a year earlier.

GlobeNewswire
Jun 3rd, 2025
Alector To Participate In The Goldman Sachs 46Th Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2024, at 8:40 am ET.A live webcast of the fireside chat will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. A replay will be available on the Alector website for 90 days following the event.About AlectorAlector is a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of genetically validated programs that aim to remove toxic proteins, replace deficient proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector’s product candidates seek to treat a range of indications, such as frontotemporal dementia, Alzheimer’s disease, and Parkinson's disease. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being selectively applied to its next-generation product candidates and research pipeline

Stock Titan
May 6th, 2025
Alector to Participate in Upcoming Healthcare Conferences

Additionally, Alector will participate in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference in New York on May 20, 2025, at 12:00 p.m. ET.

ITTBioMed
Apr 2nd, 2025
New breakthroughs in early-onset dementia: progranulin therapies show promise

In another strategy, Alector, in collaboration with GSK, is developing the monoclonal antibody latozinemab (AL001), which works by blocking progranulin degradation to boost its availability.

BioSpace
Mar 25th, 2025
Alector Cuts Staff Again, This Time Laying Off 13% of Workforce

As part of cost-cutting efforts, Alector is letting go of about 25 people as it focuses on advancing its preclinical and research pipeline.

INACTIVE